These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 35233828)
21. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973 [TBL] [Abstract][Full Text] [Related]
22. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling. Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939 [TBL] [Abstract][Full Text] [Related]
23. The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression. Liu N; Zhang J; Chen W; Ma W; Wu T J Exp Clin Cancer Res; 2023 Oct; 42(1):263. PubMed ID: 37817227 [TBL] [Abstract][Full Text] [Related]
24. YTHDF1 facilitates esophageal cancer progression via augmenting m6A-dependent TINAGL1 translation. Zhang L; Cai E; Xu Y; Liu Z; Zheng M; Sun Z; Pei D; Wang Q Cell Signal; 2024 Oct; 122():111332. PubMed ID: 39098703 [TBL] [Abstract][Full Text] [Related]
25. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway. Indramanee S; Sawanyawisuth K; Silsirivanit A; Dana P; Phoomak C; Kariya R; Klinhom-On N; Sorin S; Wongkham C; Okada S; Wongkham S Sci Rep; 2019 Nov; 9(1):17266. PubMed ID: 31754244 [TBL] [Abstract][Full Text] [Related]
26. SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance. Chen J; Gao Z; Li X; Shi Y; Tang Z; Liu W; Zhang X; Huang A; Luo X; Gao Q; Ding G; Song K; Zhou J; Fan J; Fu X; Ding Z Cancer Med; 2023 Jan; 12(1):459-471. PubMed ID: 35676831 [TBL] [Abstract][Full Text] [Related]
27. YTHDF1 promotes gallbladder cancer progression via post-transcriptional regulation of the m6A/UHRF1 axis. Chen J; Bai X; Zhang W; Yan Z; Liu Y; Zhou S; Wu X; He X; Yang A J Cell Mol Med; 2024 May; 28(9):e18328. PubMed ID: 38683130 [TBL] [Abstract][Full Text] [Related]
28. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma. Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137 [TBL] [Abstract][Full Text] [Related]
29. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma. Jin J; Ryu HS; Lee KB; Jang JJ PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299 [TBL] [Abstract][Full Text] [Related]
30. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Li Q; Ni Y; Zhang L; Jiang R; Xu J; Yang H; Hu Y; Qiu J; Pu L; Tang J; Wang X Signal Transduct Target Ther; 2021 Feb; 6(1):76. PubMed ID: 33619246 [TBL] [Abstract][Full Text] [Related]
31. MiR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma. Xiong X; Sun D; Chai H; Shan W; Yu Y; Pu L; Cheng F Biochem Biophys Res Commun; 2015 Sep; 465(2):262-9. PubMed ID: 26255969 [TBL] [Abstract][Full Text] [Related]
32. NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma. Hu S; Molina L; Tao J; Liu S; Hassan M; Singh S; Poddar M; Bell A; Sia D; Oertel M; Raeman R; Nejak-Bowen K; Singhi A; Luo J; Monga SP; Ko S Gastroenterology; 2022 Aug; 163(2):449-465. PubMed ID: 35550144 [TBL] [Abstract][Full Text] [Related]
33. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. Li P; Shi Y; Gao D; Xu H; Zou Y; Wang Z; Li W Int J Biol Sci; 2022; 18(16):6145-6162. PubMed ID: 36439881 [No Abstract] [Full Text] [Related]
34. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses. Liu B; Yan S; Jia Y; Ma J; Wu S; Xu Y; Shang M; Mao A FEBS J; 2016 Oct; 283(20):3839-3850. PubMed ID: 27616304 [TBL] [Abstract][Full Text] [Related]
35. Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD. Yang L; Niu K; Wang J; Shen W; Jiang R; Liu L; Song W; Wang X; Zhang X; Zhang R; Wei D; Fan M; Jia L; Tao K J Hepatol; 2024 Oct; 81(4):651-666. PubMed ID: 38679071 [TBL] [Abstract][Full Text] [Related]
36. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway. Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516 [TBL] [Abstract][Full Text] [Related]
37. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612 [TBL] [Abstract][Full Text] [Related]
38. DAGLβ is the principal synthesizing enzyme of 2-AG and promotes aggressive phenotype of intrahepatic cholangiocarcinoma via AP-1/DAGLβ/miR4516 feedforward circuitry. Ma M; Zeng G; Tan B; Zhao G; Su Q; Zhang W; Song Y; Liang J; Xu B; Wang Z; Chen J; Hou M; Yang C; Yun J; Huang Y; Lin Y; Chen D; Han Y; DeMorrow S; Liang L; Lai J; Huang L Am J Physiol Gastrointest Liver Physiol; 2023 Sep; 325(3):G213-G229. PubMed ID: 37366545 [TBL] [Abstract][Full Text] [Related]
39. YTHDF1 Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer Cells via Upregulating TCF7 mRNA Translation. Li Y; Guo X; Liang X; Wang Z Front Biosci (Landmark Ed); 2024 Mar; 29(3):117. PubMed ID: 38538279 [TBL] [Abstract][Full Text] [Related]
40. The role of Tripartite motif containing 59 (TRIM59) in the proliferation and prognosis of intrahepatic cholangiocarcinoma. Zhang JN; Ding DY; Yang SY; Tao QF; Yang Y; Zhou WP Pathol Res Pract; 2022 Aug; 236():153989. PubMed ID: 35753134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]